Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The RAVE 2 trial is a phase I, open label, 12-month trial of intravitreal ranibizumab 2.0 mg
in patients with ischemic CRVO who have been either previously treated with ranibizumab or
treatment naïve.